Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Loomis Sayles & Co. L P trimmed its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 290,111 shares of the company’s stock after selling 8,475 shares during the period. Loomis Sayles & Co. L P owned 0.60% of Axsome Therapeutics worth $24,547,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after acquiring an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in Axsome Therapeutics during the fourth quarter valued at approximately $2,599,000. Intech Investment Management LLC raised its position in shares of Axsome Therapeutics by 46.5% in the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after purchasing an additional 5,087 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Axsome Therapeutics in the fourth quarter worth $14,771,000. Finally, PDT Partners LLC bought a new stake in shares of Axsome Therapeutics during the 3rd quarter worth $1,052,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $118.53 on Friday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a 50-day moving average of $119.67 and a 200-day moving average of $101.09. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of -19.79 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXSM has been the topic of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Mizuho lifted their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday. Bank of America increased their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Finally, Wells Fargo & Company increased their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $167.64.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.